N V Khabarova

Metabolomic phenotype of heart failure in cardio-oncology patients

R B Alieva, K H G Fozilov, M A L I K A Yakhyoeva, N V Khabarova et autres

Abstract Background Heart failure (HF) in cardio-oncology patients during anticancer therapy is usually regarded as an accelerated form of classical HF, which restricts early diagnosis and timely pathogenetically based treatment. Myocardial decompensation in these patients appears to involve distinct molecular mechanisms detectable …

uz, ru (code pays fourni par la source)

Early lipid profile deterioration during chemotherapy as a marker of subclinical vascular toxicity and therapy rationale

R B Alieva, K H G Fozilov, M A L I K A Yakhyoeva, Y Kirichenco et autres

Abstract Background Current cardio-oncology surveillance strategies are primarily focused on patients with high or very high baseline cardiovascular (CV) toxicity risk. Patients with initially low risk are generally considered a clinically favorable group and therefore undergo less intensive monitoring. This approach may …

uz, ru (code pays fourni par la source)

Endothelin-1 as a diagnostic and prognostic biomarker of subclinical anthracycline-induced vascular toxicity in lymphoproliferative diseases patients with low and intermediate cardiotoxic risk

R B Alieva, K H G Fozilov, M A L I K A Yakhyoeva, Y U N Belenkov et autres

Abstract Abstract Anthracyclines remain a cornerstone of therapy for lymphoproliferative diseases eratie(LPD) but are associated with cardiovascular toxicity (CVT). While myocardial injury is well studied, anthracycline-induced vascular toxicity and endothelial dysfunction as early manifestations of cardiovascular damage remain insufficiently explored, particularly in …

uz, ru (code pays fourni par la source)

Эхокардиографические показатели пациентов со злокачественными новообразованиями до начала противоопухолевой терапии

Г. Е. Гендлин, Ю. А. Васюк, Е. И. Емелина, Д. А. Паэгле et autres